Pfizer Price to Free Cash Flow Ratio 2012-2026 | PFE

Historical price to free cash flow ratio values for Pfizer (PFE) since 2012.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Pfizer Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2026-06-10 25.60 14.07
2025-09-30 24.23 $1.82 13.32
2025-06-30 22.66 $2.18 10.38
2025-03-31 23.24 $1.97 11.81
2024-12-31 23.94 $1.73 13.87
2024-09-30 25.71 $1.44 17.85
2024-06-30 24.51 $0.84 29.13
2024-03-31 23.95 $0.89 26.77
2023-12-31 24.48 $0.84 29.16
2023-09-30 27.83 $1.42 19.60
2023-06-30 30.43 $1.85 16.45
2023-03-31 33.49 $3.53 9.49
2022-12-31 41.68 $4.54 9.18
2022-09-30 35.29 $4.10 8.61
2022-06-30 41.96 $4.97 8.45
2022-03-31 41.09 $5.55 7.40
2021-12-31 46.52 $5.23 8.89
2021-09-30 33.59 $5.21 6.44
2021-06-30 30.31 $3.73 8.13
2021-03-31 27.77 $2.39 11.63
2020-12-31 27.91 $2.16 12.91
2020-09-30 26.13 $1.87 13.97
2020-06-30 23.06 $2.29 10.06
2020-03-31 22.79 $2.12 10.75
2019-12-31 27.08 $1.86 14.58
2019-09-30 24.59 $1.99 12.39
2019-06-30 29.38 $2.07 14.21
2019-03-31 28.55 $2.27 12.59
2018-12-31 29.09 $2.32 12.56
2018-09-30 29.14 $2.68 10.89
2018-06-30 23.79 $2.63 9.05
2018-03-31 23.04 $2.51 9.17
2017-12-31 23.30 $2.45 9.51
2017-09-30 22.76 $2.27 10.04
2017-06-30 21.21 $2.23 9.50
2017-03-31 21.39 $2.29 9.33
2016-12-31 20.10 $2.33 8.62
2016-09-30 20.76 $2.15 9.66
2016-06-30 21.40 $2.21 9.70
2016-03-31 17.86 $2.30 7.78
2015-12-31 19.25 $2.12 9.06
2015-09-30 18.58 $2.25 8.25
2015-06-30 19.68 $2.16 9.13
2015-03-31 20.26 $2.13 9.49
2014-12-31 17.98 $2.47 7.27
2014-09-30 16.92 $2.37 7.13
2014-06-30 16.83 $2.61 6.45
2014-03-31 18.06 $2.51 7.20
2013-12-31 17.08 $2.39 7.15
2013-09-30 15.90 $2.27 7.00
2013-06-30 15.37 $2.00 7.67
2013-03-31 15.71 $2.01 7.81
2012-12-31 13.53 $2.05 6.59
2012-09-30 13.29 $2.04 6.52
2012-06-30 12.19 $1.94 6.29
2012-03-31 11.88 $2.15 5.54
2011-12-31 11.24 $2.36 4.76
2011-09-30 9.09 $2.49 3.65
2011-06-30 10.47 $2.75 3.81
2011-03-31 10.23 $2.60 3.93
2010-12-31 8.73 $1.23 7.09
2010-09-30 8.47 $1.08 7.81
2010-06-30 6.96 $0.86 8.11
2010-03-31 8.28 $0.93 8.88
2009-12-31 8.70 $2.18 3.98
2009-09-30 7.84 $2.45 3.20
2009-06-30 7.03 $2.40 2.93
2009-03-31 6.32 $2.47 2.56
2008-12-31 8.04 $2.45 3.28
2008-09-30 8.22 $2.07 3.98
2008-06-30 7.67 $2.16 3.54
2008-03-31 9.04 $1.94 4.67
2007-12-31 9.68 $1.65 5.85
2007-09-30 10.28 $1.74 5.91
2007-06-30 10.63 $1.61 6.62
2007-03-31 10.39 $1.78 5.82
2006-12-31 10.54 $2.14 4.93
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $153.074B $62.579B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
Johnson & Johnson (JNJ) United States $574.358B 22.08
AbbVie (ABBV) United States $367.673B 20.79
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novartis AG (NVS) Switzerland $293.951B 17.16
Novo Nordisk (NVO) Denmark $167.527B 9.60
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70
Innoviva (INVA) United States $1.760B 5.88